<!DOCTYPE HTML>
<!DOCTYPE html PUBLIC "" ""><HTML lang="en" lang="en" xml:lang="en" xmlns="http://www.w3c.org/1999/xhtml"><HEAD><META 
content="IE=11.0000" http-equiv="X-UA-Compatible">
     
<META http-equiv="content-type" content="text/html; charset=utf-8">     
<TITLE>L36_C</TITLE>     
<META name="title" content="NHANES 2003-2004: Syphilis-IgG, Syphilis Rapid Plasma Reagin (RPR) &amp; Treponema pallidum Particle Agglutination (TP-PA) Data Documentation, Codebook, and Frequencies"> 
    
<STYLE type="text/css">
					.nhanes-doc { font: 75% Verdana, Arial, Helvetica, sans-serif; }

					.nhanes-doc h1 {
					color: #0c5205;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 2em;
					font-weight: normal;
					margin-bottom: 10px;
					margin-top: 0;
					}

					.nhanes-doc h2 {
					color: #0c5205;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.6em;
					font-weight: normal;
					}

					.nhanes-doc h3 {
					color: #000;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.5em;
					font-weight: normal;
					}

					.nhanes-doc h3.vartitle {
					background-color: #c1d5b0;
					padding: 6px 12px;
					}

					.nhanes-doc h4 {
					color: #000;
					font-family: "Trebuchet MS", Arial, sans-serif;
					font-size: 1.3em;
					font-weight: bold;
					}

					.nhanes-doc h5 {
					color: #000;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1em;
					font-weight: bold;
					}

					.nhanes-doc h5.specialnote {
					color: #000;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1.2em;
					font-style: italic;
					font-weight: bold;
					}

					.nhanes-doc a {
					color: #039;
					text-decoration: none;
					}

					.nhanes-doc p {
					font-family: Verdana, Arial, Helvetica, sans-serif;
					font-size: 1em;
					line-height: 1.33em;
					margin: 0 3em 1em;
					padding: 0;
					text-align: left;
					}

					.nhanes-doc ul {
					list-style-type: disc;
					margin: 0 3em 1em;
					padding: 0;
					}

					.nhanes-doc ol {
					list-style-type: decimal;
					margin: 0;
					overflow: hidden;
					padding: 0;
					padding-left: 2em;
					}

					.nhanes-doc li {
					margin-left: 1.5em;
					margin-top: 0.7em;
					}

					.nhanes-doc table {
					border: #000 1px solid;
					border-collapse: collapse;
					margin: 0 auto 1em;
					max-width: 600px;
					padding: 2px;
					page-break-inside: avoid;
					table-layout: auto;
					}

					.nhanes-doc th {
					background: #f4f4e1;
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: center;
					vertical-align: top;
					}

					.nhanes-doc th.rowheader {
					background: #f4f4e1;
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: center;
					vertical-align: top;
					}

					.nhanes-doc td {
					border: #000 1px solid;
					font-family: Verdana, Arial, Helvetica, sans-serif;
					padding: 5px;
					text-align: left;
					vertical-align: top;
					}

					.nhanes-doc td.values2 {
					text-align: RIGHT;
					vertical-align: top;
					}

					.nhanes-doc table caption {
					font-weight: bold;
					padding-bottom: 0.5em;
					}

					.nhanes-doc div#wrapper { width: 650px; }

					.nhanes-doc div#toc {
					border: solid 1px #CCC;
					float: left;
					height: 95%;
					left: 750px;
					overflow: hidden;
					position: fixed;
					top: 10px;
					width: 400px;
					z-index: 10;
					}

					.nhanes-doc div#toc h3 {
					background-color: #f4f4e1;
					border-bottom: solid 1px #ccc;
					letter-spacing: 8px;
					margin: 0;
					padding: 8px;
					text-align: center;
					text-transform: uppercase;
					}

					.nhanes-doc div#toc-scroll {
					height: calc(100% - 1.5em);
					overflow: scroll;
					width: 100%;
					}

					.nhanes-doc div#toc li {
					margin-left: -0.5em;
					margin-right: -0.5em;
					}

					.nhanes-doc div#PageHeader {
					border-bottom: thin solid #999;
					margin-bottom: 12px;
					width: 650px;
					}

					.nhanes-doc div#Sections { width: 650px; }

					.nhanes-doc div#Codebook { width: 650px; }

					.nhanes-doc div#Codebook dl {
					margin: 2em 0 10px 40px;
					padding: 0;
					width: 600px;
					display: table;
					}

					.nhanes-doc div#Codebook dt {
					float: left;
					font-weight: bold;
					margin: 0;
					padding: 0.5em;
					width: 150px;
					display: table-cell;
					}

					.nhanes-doc div#Codebook dd {
					float: left;
					margin: 0;
					padding: 0.5em;
					width: 420px;
					display: table-cell;
					}

					.nhanes-doc div#References {
					page-break-after: always;
					width: 650px;
					}

					.nhanes-doc div#Appendix {
					page-break-after: always;
					width: 650px;
					}

					.nhanes-doc table.values {
					border: 2px;
					left: 20px;
					margin-bottom: 20px;
					page-break-inside: avoid;
					position: relative;
					width: 600px;
					}

					.nhanes-doc span.file-size { color: gray; }

					.nhanes-doc .pagebreak {
					background-color: transparent;
					display: block;
					page-break-after: always;
					page-break-inside: avoid;
					}
				</STYLE>
     
<STYLE type="text/css" media="print">
					.nhanes-doc div#toc { display: none; }
				</STYLE>
   </HEAD>   
<BODY class="nhanes-doc">
<DIV id="toc">
<H3>Table of Contents</H3>
<DIV id="toc-scroll">
<UL>
  <LI><A href="#Component_Description">Component Description</A>           </LI>
  <LI><A href="#Eligible_Sample">Eligible Sample</A>           </LI>
  <LI><A href="#Description_of_Laboratory_Methodology">Description of Laboratory 
  Methodology</A>           </LI>
  <LI><A href="#Laboratory_Quality_Assurance_and_Monitoring">Laboratory Quality 
  Assurance and Monitoring</A>           </LI>
  <LI><A href="#Data_Processing_and_Editing">Data Processing and Editing</A>     
        </LI>
  <LI><A href="#Analytic_Notes">Analytic Notes</A>           </LI>
  <LI><A href="#References">References</A>           </LI>
  <LI><A href="#Codebook">Codebook</A>             
  <UL id="CodebookLinks">
    <LI><A href="#SEQN">SEQN - Respondent sequence number</A>               
</LI>
    <LI><A href="#LBXSY1">LBXSY1 - Syphilis IgG EIA</A>               </LI>
    <LI><A href="#LBDSY3">LBDSY3 - Syphilis RPR Titer Level</A>               
    </LI>
    <LI><A href="#LBDSY4">LBDSY4 - Syphilis TP-PA</A>               
</LI></UL></LI></UL></DIV></DIV>
<DIV id="wrapper">
<DIV id="PageHeader">
<H1>National Health and Nutrition Examination Survey</H1>
<H2>2003-2004 Data Documentation, Codebook, and Frequencies</H2>
<H3>Syphilis-IgG, Syphilis Rapid Plasma Reagin (RPR) &amp; Treponema pallidum 
Particle Agglutination (TP-PA) (L36_C)</H3>
<H4> Data File: L36_C.xpt</H4>
<H5 class="left">First Published: January 2006</H5>
<H5 class="right">Last Revised: April 2006</H5></DIV>
<DIV id="Sections">
<H2 id="Component_Description">Component Description</H2>
<P>Although there has been a marked decrease in the number of primary and 
secondary syphilis cases in the United States, there has been very little 
decrease in the number of reported cases of late latent and tertiary syphilis 
over the past 20 years. This suggests that there may be a large pool of infected 
but asymptomatic persons. Although the primary and secondary stages of syphilis 
are infectious and associated with fetal wastage and the congenital syphilis 
syndrome, the tertiary stage is associated with a vasculitis that may cause 
neurologic and cardiovascular manifestations and other chronic problems. 
Similarly, primary and secondary syphilis increase the risk of HIV acquisition 
and transmission, while latent disease may be associated with the progression of 
HIV disease to AIDS and more prominent neurologic disease in HIV-infected 
persons. Despite the importance of syphilis as a risk factor for both chronic 
disease and the progression of HIV infection, there has not been a 
population-based measure of syphilis prevalence for the United States since 
1980. Because these are often asymptomatic stages of infection and may lead to 
severe neurologic or cardiovascular complications, it is important to document a 
decrease in the late stages of syphilis that have resulted from our 
extraordinary efforts to reduce primary and secondary syphilis. NHANES offers a 
unique opportunity to estimate the prevalence of reactive serologic tests as an 
estimate of the prevalence of syphilis infections in the general population, to 
identify and confirm risk factors for syphilis, to confirm the risk for HIV 
infection and HIV-related neurologic disease among Americans with syphilis, and 
to monitor trends in prevalence as syphilis detection and treatment programs are 
established and expanded.</P>
<H2 id="Eligible_Sample">Eligible Sample</H2>
<P>Participants aged 18–49 years were tested.</P>
<H2 id="Description_of_Laboratory_Methodology">Description of Laboratory 
Methodology</H2>
<P><STRONG>Syphilis-G enzyme immunoassay (EIA)</STRONG> </P>
<P>The Captia Syphilis-G enzyme immunoassay (EIA) is an indirect method for the 
detection of IgG antibodies to <EM>Treponema pallidum. </EM>Currently, CDC 
recommends that the test be used in the clinical laboratory as a confirmatory 
test for the diagnosis of syphilis. However, the test may be used as a screening 
test and is FDA-approved for such use in clinical laboratories and blood banks. 
<EM>T. pallidum</EM> antigens are coated onto the wells of a 96-well microtiter 
plate. A dilution of the patient’s serum is added to the well to allow any 
<EM>T. pallidum</EM>-specific antibodies present to bind to the treponemal 
antigens. Biotinylated anti-human IgG labeled with strepavidin-peroxidase is 
used to detect the patient’s antibody. After rinsing off the excess antibodies, 
an enzyme substrate is added for detection. If the patient has antibodies to 
<EM>T. pallidum</EM>, a color reaction takes place. The intensity of the color 
development is proportional to the amount of antibody present. This color change 
can then be read using a plate reader, which eliminates subjective 
interpretation of the results. </P>
<P><STRONG>Rapid plasma reagin (RPR)</STRONG> </P>
<P>The Rapid plasma reagin (RPR) 18-mm circle card test is a macroscopic, 
nontreponemal flocculation card test used to screen for syphilis. The antigen is 
prepared from a modified Venereal Disease Research Laboratory (VDRL) antigen 
suspension containing choline chloride to eliminate the need to heat-inactivate 
serum, ethylene-diamine-tetra-acetic acid (EDTA) to enhance the stability of the 
suspension, and finely divided charcoal particles as a visualizing agent. In the 
test, the RPR antigen is mixed with unheated or heated serum or with unheated 
plasma on a plastic-coated card. The RPR test measures IgM and IgG antibodies to 
lipoidal material released from damaged host cells, as well as to 
lipoprotein-like material and possibly cardiolipin released from the treponemes. 
The anti-lipoidal antibodies are antibodies that are produced not only as a 
consequence of syphilis and other treponemal diseases, but also in response to 
nontreponemal diseases of an acute and chronic nature in which tissue damage 
occurs. If antibodies are present, they combine with the lipid particles of the 
antigen, causing them to agglutinate. The charcoal particles coagglutinate with 
the antibodies and show up as black clumps against the white card. If antibodies 
are not present, the test mixture is uniformly gray. The test can be purchased 
in kit form or in component parts from many commercial sources. Without some 
other evidence for the diagnosis of syphilis, a reactive nontreponemal test does 
not confirm <EM>T. pallidum </EM>infection. </P>
<P><EM>Treponema pallidum</EM> particle agglutination (TP-PA) </P>
<P>The Serodia TP-PA test is a treponemal test for the serologic detection of 
antibodies to the various species and subspecies of pathogenic 
<EM>Treponema</EM>, the causative agents of syphilis, yaws, pinta, bejel, and 
endemic syphilis. The test is a passive agglutination procedure based on the 
agglutination of gel particles sensitized with <EM>T. pallidum</EM> antigens by 
antibodies found in the patient's serum. The test is intended as a confirmatory 
test to replace the microhemagglutination assay for antibodies to <EM>T. 
pallidum</EM> (MHA-TP). </P>
<P>Serum containing antibodies to pathogenic treponemes reacts with gel 
particles sensitized with sonicated <EM>T. pallidum</EM>, Nichols strain (the 
antigen), to form a smooth mat of agglutinated gel particles in the microtiter 
tray well. If antibodies are not present, the particles settle to the bottom of 
the tray well, forming a characteristic compact button of unagglutinated 
particles. The unsensitized gel particle control well for each serum should also 
show this compact button or the absence of agglutination. </P>
<P>The TP-PA test is used to confirm the reactive results of a nontreponemal 
screening test for syphilis, such as the VDRL slide test, or as a diagnostic 
test in patients with a nonreactive nontreponemal test but with signs or 
symptoms suggestive of late syphilis. </P>
<P>There were no changes to equipment, lab methods, or lab site from the 
previous 2 years of NHANES. A detailed description of the laboratory method used 
can be found on the NHANES website.</P>
<H2 id="Laboratory_Quality_Assurance_and_Monitoring">Laboratory Quality 
Assurance and Monitoring</H2>
<P>The NHANES quality assurance and quality control (QA/QC) protocols meet the 
1988 Clinical Laboratory Improvement Act mandates. Detailed quality control and 
quality assurance instructions are discussed in the NHANES LPM. Read the LABDOC 
file for detailed QA/QC protocols. </P>
<P>A detailed description of the quality assurance and quality control 
procedures can be found on the NHANES website.</P>
<H2 id="Data_Processing_and_Editing">Data Processing and Editing</H2>
<P>Serum specimens were processed, stored and shipped to Division of STD 
Prevention Laboratory, National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention,&nbsp;Centers for Disease Control and Prevention, Atlanta, GA. 
Detailed specimen collection and processing instructions are discussed in the 
NHANES LPM. Read the LABDOC file for detailed data processing and editing 
protocols. The analytical methods are described in the Description of the 
Laboratory Methodology section. </P>
<P>Detailed instructions on specimen collection and processing can be found on 
the NHANES website.</P>
<H2 id="Analytic_Notes">Analytic Notes</H2>
<P>The analysis of NHANES 2003–2004 laboratory data must be conducted with the 
key survey design and basic demographic variables. The NHANES 2003–2004 
Household Questionnaire Data Files contain demographic data, health indicators, 
and other related information collected during household interviews. They also 
contain all survey design variables and sample weights for these age groups. The 
phlebotomy file includes auxiliary information such as the conditions precluding 
venipuncture. The household questionnaire and phlebotomy files may be linked to 
the laboratory data file using the unique survey participant identifier SEQN. 
</P>
<P><STRONG>Testing algorithm for NHANES specimens</STRONG> </P>
<P>All serum specimens were tested for IgG antibody by the EIA assay. If results 
of this assay were positive or equivocal, the specimens were tested using the 
RPR test. If the RPR test was nonreactive or had a titer &lt; 1:8, the TP-PA 
test was performed on the sample. </P>
<P>Suggested interpretation of laboratory results: </P>
<P>LBXSY1 = Syphilis-G enzyme immunoassay (EIA) <BR> LBDSY3 = Rapid plasma 
reagin (RPR) <BR> LBDSY4 = Treponema pallidum particle agglutination (TP-PA) 
</P>
<P>Positive serologic evidence of syphilis, more likely recent infection: </P>
<P>(LBXSY1 = 1 or LBXSY1 = 3) and (LBDSY3 ≥ 8) </P>
<P>Positive serologic evidence of syphilis, more likely remote infection: </P>
<P>(LBXSY1 = 1 or LBXSY1 = 3) and <BR> (0 ≤&nbsp; LBDSY3 &lt; 8) and (LBDSY4 = 
1) </P>
<P>No serologic evidence of syphilis infection: </P>
<P>LBXSY1 = 2 <BR> or <BR> (LBXSY1 = 1 or LBXSY1 = 3) and (0 ≤ LBDSY3 &lt; 8) 
and <BR> (LBDSY4 = 2)</P></DIV>
<DIV id="References">
<H2>References</H2>
<UL>
  <LI>Belisle JT, Brandt ME, et al. Fatty acids of Treponema pallidum and 
  Borrelia burgdorferi lipoproteins. J Bacteriol. 1994;176:2151–2157.</LI>
  <LI>Catterall, RD. Presidential address to the M.S.S.V.D.: Systemic disease 
  and the biological false-positive reaction. Br J Vener Dis. 1972;48:1–12.</LI>
  <LI>Deguchi M, Hosotsubo H, Yamashita N, Ohmine T, Asari S. Evaluation of 
  gelatin particle agglutination method for detection of Treponema pallidum 
  antibody. J Japanese Assoc. Inf Dis. 1994; 68:1271–1277.</LI>
  <LI>Lefevre JC, Bertrand MA, Bauriaud R. Evaluation of the Captia enzyme 
  immunoassays for detection of immunoglobulins G and M to Treponema pallidum in 
  syphilis. J Clin Microbiol. 1990;28:1704–1707.</LI>
  <LI>Matthews HM, Yang TK, Jenkin HM. Unique lipid composition of Treponema 
  pallidum (Nichols virulent strain). Infect Immun. 1979;24:713–719.</LI>
  <LI>Nayar R, Campos JM. Evaluation of the DCL Syphilis-G enzyme immunoassay 
  test kit for the serologic diagnosis of syphilis. Amer J Clin Pathol. 
  1993;99:282–285.</LI>
  <LI>Pope V, Fears MB, Morrill WE, Castro A, Kikkert SE. 2000. Comparison of 
  the Serodia Treponema pallidum particle agglutination, Captia Syphilis-G, and 
  SpiroTek Reagin II tests with standard test techniques for diagnosis of 
  syphilis. J Clin Microbiol. 38:2543–2545.</LI>
  <LI>Pope V, Fears MB. Captia Syphilis-G: an enzyme immunoassay for treponemal 
  antibodies. In: Larsen SA, Pope V, Johnson RE, Kennedy EJ (ed.) A manual of 
  tests for syphilis. American Public Health Association, Washington, DC. 
  1998:332–345.</LI>
  <LI>Pope V, Fears MB. Serodia Treponema pallidum passive particle 
  agglutination (TP-PA) test, In: Larsen SA, Pope V, Johnson, RE, and Kennedy 
  EJ, Jr. (eds). A Manual of Tests for Syphilis, Supplement. American Public 
  Health Association, Washington, DC. 2000:363–378.</LI>
  <LI>Portnoy J, Brewer JH, Harris A. Rapid plasma reagin card test for syphilis 
  and other treponematoses. Public Health Rep. 1962;77:645–652.</LI>
  <LI>Portnoy J. A note on the performance of modifications of the rapid plasma 
  reagin (RPR) card test for syphilis, for use in large scale testing. Public 
  Hlth Lab. 1965;23:43.</LI>
  <LI>Portnoy J. Modifications of the rapid plasma reagin (RPR) card test for 
  syphilis, for use in large scale testing. Am J Clin Pathol. 
  1963;40:473–479.</LI>
  <LI>RPR Macro-Vue Card Test - Procedures Manual. Hynson Westcott and Dunning: 
  Baltimore, MD 1977.</LI>
  <LI>Silletti RP. Comparison of CAPTIA Syphilis G enzyme immunoassay with rapid 
  plasma reagin test for detection of syphilis. J Clin Microbiol. 
  1995;33:1829–1831.</LI>
  <LI>Young H, Moyes A, Ross JD. Markers of past syphilis in HIV infection 
  comparing Captia Syphilis G anti-treponemal IgG enzyme immunoassay with other 
  treponemal antigen tests. Int J STD AIDS. 1995;6:101–104.</LI></UL></DIV>
<DIV id="Codebook">
<H2>Codebook and Frequencies</H2>
<DIV class="pagebreak">
<H3 class="vartitle" id="SEQN">SEQN - Respondent sequence number</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">SEQN</DD>
  <DT>SAS Label: </DT>
  <DD>Respondent sequence number</DD>
  <DT>English Text: </DT>
  <DD class="info">Respondent sequence number.</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBXSY1">LBXSY1 - Syphilis IgG EIA</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBXSY1</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis IgG EIA</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis IgG EIA</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">1</TD>
    <TD class="values">Positive</TD>
    <TD align="right" class="values">53</TD>
    <TD align="right" class="values">53</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">2</TD>
    <TD class="values">Negative</TD>
    <TD align="right" class="values">2676</TD>
    <TD align="right" class="values">2729</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">3</TD>
    <TD class="values">Indeterminate</TD>
    <TD align="right" class="values">10</TD>
    <TD align="right" class="values">2739</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">237</TD>
    <TD align="right" class="values">2976</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBDSY3">LBDSY3 - Syphilis RPR Titer Level</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBDSY3</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis RPR Titer Level</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis RPR (rapid plasmin test) titer level</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">0 to 32</TD>
    <TD class="values">Range of Values</TD>
    <TD align="right" class="values">63</TD>
    <TD align="right" class="values">63</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">2913</TD>
    <TD align="right" class="values">2976</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV>
<DIV class="pagebreak">
<H3 class="vartitle" id="LBDSY4">LBDSY4 - Syphilis TP-PA</H3>
<DL>
  <DT>Variable Name: </DT>
  <DD class="info">LBDSY4</DD>
  <DT>SAS Label: </DT>
  <DD>Syphilis TP-PA</DD>
  <DT>English Text: </DT>
  <DD class="info">Syphilis treponemal pallidum agglutin (TPA)</DD>
  <DT>Target: </DT>
  <DD> Both males and females 18 YEARS -			49 YEARS</DD></DL>
<TABLE class="values">
  <THEAD>
  <TR>
    <TH class="values" scope="column">Code or Value</TH>
    <TH class="values" scope="column">Value Description</TH>
    <TH class="values" scope="column">Count</TH>
    <TH class="values" scope="column">Cumulative</TH>
    <TH class="values" scope="column">Skip to Item</TH></TR></THEAD>
  <TBODY>
  <TR>
    <TD class="values" scope="row">1</TD>
    <TD class="values">Positive</TD>
    <TD align="right" class="values">26</TD>
    <TD align="right" class="values">26</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">2</TD>
    <TD class="values">Negative</TD>
    <TD align="right" class="values">32</TD>
    <TD align="right" class="values">58</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">3</TD>
    <TD class="values">Indeterminate</TD>
    <TD align="right" class="values">0</TD>
    <TD align="right" class="values">58</TD>
    <TD class="values"></TD></TR>
  <TR>
    <TD class="values" scope="row">.</TD>
    <TD class="values">Missing</TD>
    <TD align="right" class="values">2918</TD>
    <TD align="right" class="values">2976</TD>
    <TD class="values"></TD></TR></TBODY></TABLE></DIV></DIV></DIV></BODY></HTML>
